Background: Tyrosine kinase inhibitors (TKIs) are effective in EGFR and ALK driven non-small cell lung cancer (NSCLC). However, drug insensitivity, tumor recurrence, and resistance caused by second mutations in the EGFR or aberrant bypass signaling are key challenges. To overcome this, the focus has been shifted to genomic analysis of various EGFRdownstream signaling pathways. One of the vital EGFR downstream signaling pathways that perhaps provide roadmaps for targeted therapy is MAP kinase pathway. We aim to study key genes of MAP kinase pathway in patients with pulmonary adenocarcinomas (PADC). Methods: All PADC patients since 2015 were included after obtaining clinical details. Histomorphology was ascertained prior to mutational analysis. Real-Time PCR (EGFRexon 18-21 and KRASexon 2) and Sanger Sequencing (BRAFexon 11 and 15 and MEK1exon 2) technologies were used. The clinical and pathologic correlation was done. Results: Of 118 PADC patients (M: F-2.3:1), 26.2% (31/ 118) patients harboured EGFR mutations and were predominantly females. The most common EGFR mutation was exon 19 deletion. EGFR mutation positive cases showed mostly acinar histology. KRAS mutations (G12A) were observed in 21.1% (25/118) patients and were predominantly older males with mucinous histology. Four (3.3%) patients harboured coexisting EGFR and KRAS mutations. BRAF mutations (L597V, I953V) were seen in 2.5% (3/118) patients, however, there was no coexistence of BRAF mutations with other oncogenic drivers such as KRAS, EGFR mutations or ALK fusion. Additionally, BRAFpolymorphism was seen in 15.0% cases. None of the cases showed MEK1 mutation. Conclusions: This study examined the genetic alterations of genes involved in MAP kinase pathway in PADC of Indian patients. The frequency of KRAS mutation is higher than reported previously in the literature. Secondly, mutations in EGFR and KRAS showed coexistence. The high rate of KRAS mutations and coexistence of genomic alterations in Indian patients should be validated in a large number of cases for better patient management.
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Prevalence and spectrum of germline mutations among patients with familial lung cancer M. Kanwal University Chinese Academy of Sciences, Kunming Institute of Zoology, Kunming, China Background: Although lung cancer is generally thought to be environmentally provoked but rare familial forms of lung cancer has been described previously, suggesting there may be genetic susceptibility factors. However, due to the apparently sporadic nature of lung cancer, little attention has been paid to the role of genetic predisposition in lung cancer. To address this, we used FLC samples obtained from the Chinese population in highly airpolluted regions to screen for novel germline mutations in lung cancer. Methods: Through a whole genome sequencing (WGS) analysis of the nine subjects (four lung cancer patients and five normal family members of FLC), we obtained a whole genome dataset of DNA alterations in FLC samples. A total of 1218 genes were identified with mutations of multiple types. Subsequently, the top 12 highly mutated genes were selected for validation by PCR and DNA sequencing in an expanded sample set including FLC, sporadic lung cancer, and healthy population. Results: Mutations of the five genes (ARHGEF5, ANKRD20A2, ZNF595, ZNF812, MYO18B) may be potential germline mutations of lung cancer. We also analyzed specific mutations within the 12 genes and found that some specific mutations within the MUC12, FOXD4L3 and FOXD4L5genes showed higher frequencies in the samples of FLC and/or lung cancer tissue, compared with the healthy population. Moreover, some genes with copy number variation may be potentially associated with a predisposition to lung cancer. Conclusions: Our study uncovered the mutation spectrum in FLC of the Chinese population. Insights from this study will help direct further efforts to enhance our understanding of genetic predisposition in lung cancer. The investigation of novel and known gene mutations detected by the present study may contribute to evaluate functional impacts of these mutations not only in FLC but in sporadic lung cancer as well. Legal entity responsible for the study: N/A Funding: National Science Foundation of China (81272617), the 973 Program (2011CB510104), and the Yunnan Province Science and Technology Department (Y103951111) Disclosure: All authors have declared no conflicts of interest.
